Skip to main content
SpringerLink
Log in

Medicines Save, Medicines Kill

  • Editorial
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 25 February 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Onakpoya I, Heneghan C, Aronson J. Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: an analysis of justification. Drug Safety. 2017;40(5):431–41.

  2. Mullard A. Mediator scandal rocks French medical community. Lancet. 2011;377:890–2.

    Article  PubMed  Google Scholar 

  3. World Health Organization. The world medicines situation. Geneva: World Health Organization; 2004.

    Google Scholar 

  4. Pal S, Dodoo A, Mantel A, Olsson S. The world medicines situation 2011: pharmacovigilance and safety of medicines. Geneva: World Health Organization; 2011.

    Google Scholar 

  5. Kamal-Yanni M, Saunders P. Urgent need for WHO’s reform to prioritise core functions. Lancet. 2012;379:1878.

    Article  PubMed  Google Scholar 

  6. La Rochelle P, Lexchin J, Simonyan D. Analysis of the drugs withdrawn from the US market from 1976 to 2010 for safety reasons. Pharm Med. 2016;20:277–89.

    Article  Google Scholar 

  7. Lexchin J. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Med. 2014;8:e14–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lis Y, Roberts M, Kamble S, Guo J, Raisch D. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and Outcomes Research risk benefit management working group. Value Health. 2012;15:1108–18.

    Article  PubMed  Google Scholar 

  9. Fain K, Daubresse M, Alexander G. The food and drug administration amendments act and postmarketing commitments. JAMA. 2013;310:202–4.

    Article  CAS  PubMed  Google Scholar 

  10. Lundh A, Lexchin J, Mintzes B, Schroll J, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;(2):MR000033. doi:10.1002/14651858.MR000033.pub3.

  11. Kesselheim A, Avorn J. New, “21st century cures” legislation: speed and ease vs science. JAMA. 2017;317:581–2.

    Article  PubMed  Google Scholar 

  12. Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. “Adaptive pathways” to drug authorization: adapting to industry? BMJ. 2016;354:i4437.

    Article  PubMed  Google Scholar 

  13. Carpenter D, Zucker E, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358:1354–61.

    Article  CAS  PubMed  Google Scholar 

  14. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172:1680–1.

    Article  PubMed  Google Scholar 

  15. Moore T, Singh S, Furberg C. The FDA and new safety warnings. Arch Intern Med. 2012;172:78–80.

    Article  PubMed  Google Scholar 

  16. Auditor General of Canada. Chapter 4: regulating pharmaceutical drugs. Ottawa: Health Can; 2011.

    Google Scholar 

  17. Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton, NJ: Princeton University Press; 2010.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Health Policy and Management, York University, 4700 Keele Street, Toronto, ON, M3J 1P3, Canada

    Joel Lexchin

  2. University Health Network, Toronto, ON, Canada

    Joel Lexchin

  3. Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada

    Joel Lexchin

Authors
  1. Joel Lexchin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Lexchin.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this commentary.

Conflicts of interest

In 2015–2016, Joel Lexchin received payment from non-profit organizations for being a consultant on a project to investigate indication-based prescribing, and a project that looked into which drugs should be provided free of charge by primary care providers. He received payment from a for-profit organization for being on a panel that discussed extending drug insurance in Canada. He is on the Foundation Board for Health Action International.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lexchin, J. Medicines Save, Medicines Kill. Drug Saf 40, 457–459 (2017). https://doi.org/10.1007/s40264-017-0521-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-017-0521-6

Keywords

Search

Navigation